Legal / IP

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer
HKG: 6628Patents

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer

Transcenta Holding Limited (HKG: 6628) announced that it has been granted an invention patent by the China National Intellectual Property Administration (CNIPA) covering the anti-CLDN18.2 antibodies independently developed by the…

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
AbbottDiabetes

UPC Appeal Court Reverses Lower Ruling, Imposes Preliminary Injunction on Sinocare’s iCanCGM App in 17 European Countries Following Abbott Patent Claim

ETR: SHLSiemens Healthineers

Siemens Healthineers Partners with Shanghai’s Ruijin Hospital on World’s First AI-Powered Liver Fat Quantification Software

YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China
HKG: 2496Patents

YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China

BeOne Medicines Terminates Patent Dispute with AbbVie’s Pharmacyclics Over BTK Inhibitors
AbbVieBeOne Medicines

BeOne Medicines Terminates Patent Dispute with AbbVie’s Pharmacyclics Over BTK Inhibitors

Show More